{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:44:46Z","timestamp":1789595086016,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["72038820CA00002"],"award-info":[{"award-number":["72038820CA00002"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40121-025-01127-0","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:38:35Z","timestamp":1742942315000},"page":"803-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Xpert MTB\/XDR Assay for Detection of Resistance to Isoniazid, Fluoroquinolone, Aminoglycoside, and Ethionamide Among Patients with Pulmonary Tuberculosis in Bangladesh"],"prefix":"10.1007","volume":"14","author":[{"given":"S. M. Mazidur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noshin Nawer","family":"Ruhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiyo","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Jahid","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumana","family":"Nasrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahammad Shafiq Sikder","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Khaja Mafij","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung Kya Jai","family":"Maug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-1962","authenticated-orcid":false,"given":"Sayera","family":"Banu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"1127_CR1","unstructured":"Organization WH. Global Tuberculosis Report 2024. 2024. worldhealthorgshinyappsio\/tb_profiles\/?_inputs_&tab=tables&lan=EN&entity_type=group&group_code=global. 2024."},{"key":"1127_CR2","unstructured":"World Health Organization. Tuberculosis profile: Bangladesh. 2024. https:\/\/worldhealthorg.shinyapps.io\/tb_profiles\/?_inputs_&tab=%22tables%22&lan=%22EN%22&iso2=%22BD%22&entity_type=%22country%22."},{"issue":"1","key":"1127_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1128\/JCM.02378-13","volume":"52","author":"S Banu","year":"2014","unstructured":"Banu S, Rahman SM, Khan MS, et al. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol. 2014;52(1):156\u201363. https:\/\/doi.org\/10.1128\/JCM.02378-13.","journal-title":"J Clin Microbiol"},{"key":"1127_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/diagnostics12020410","volume":"12","author":"SMM Rahman","year":"2022","unstructured":"Rahman SMM, Ather MF, Nasrin R, et al. Performance of WHO-endorsed rapid tests for detection of susceptibility to first-line drugs in patients with pulmonary tuberculosis in Bangladesh. Diagnostics. 2022;12:2. https:\/\/doi.org\/10.3390\/diagnostics12020410.","journal-title":"Diagnostics"},{"issue":"1","key":"1127_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/jcm.01463-09","volume":"48","author":"D Helb","year":"2010","unstructured":"Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010;48(1):229\u201337. https:\/\/doi.org\/10.1128\/jcm.01463-09.","journal-title":"J Clin Microbiol"},{"key":"1127_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1128\/mBio.00812-17","volume":"8","author":"S Chakravorty","year":"2017","unstructured":"Chakravorty S, Simmons AM, Rowneki M, et al. The new Xpert MTB\/RIF ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. MBio. 2017;8:4. https:\/\/doi.org\/10.1128\/mBio.00812-17.","journal-title":"MBio"},{"key":"1127_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/jcm.02314-20","volume":"59","author":"Y Cao","year":"2021","unstructured":"Cao Y, Parmar H, Gaur RL, et al. Xpert MTB\/XDR: a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum. J Clin Microbiol. 2021;59:3. https:\/\/doi.org\/10.1128\/jcm.02314-20.","journal-title":"J Clin Microbiol"},{"key":"1127_CR8","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: Diagnosis \u2013 Rapid diagnostics for tuberculosis detection 2024. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/nbk602005\/."},{"issue":"3","key":"1127_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119628","volume":"10","author":"M Seifert","year":"2015","unstructured":"Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS ONE. 2015;10(3): e0119628. https:\/\/doi.org\/10.1371\/journal.pone.0119628.","journal-title":"PLoS ONE"},{"issue":"6","key":"1127_CR10","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1007\/s15010-024-02260-7","volume":"52","author":"S Sethi","year":"2024","unstructured":"Sethi S, Sharma S, Aggarwal AN, et al. Xpert MTB\/XDR assay: rapid TB drug resistance detection. Infection. 2024;52(6):2207\u201312. https:\/\/doi.org\/10.1007\/s15010-024-02260-7.","journal-title":"Infection"},{"issue":"8","key":"1127_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284545","volume":"18","author":"A Katamba","year":"2023","unstructured":"Katamba A, Ssengooba W, Sserubiri J, et al. Evaluation of Xpert MTB\/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda. PLoS ONE. 2023;18(8): e0284545. https:\/\/doi.org\/10.1371\/journal.pone.0284545.","journal-title":"PLoS ONE"},{"issue":"8","key":"1127_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00229-24","volume":"62","author":"SV Omar","year":"2024","unstructured":"Omar SV, Louw G, Ismail F, et al. Performance evaluation of the Xpert MTB\/XDR test for the detection of drug resistance to Mycobacterium tuberculosis among people diagnosed with tuberculosis in South Africa. J Clin Microbiol. 2024;62(8): e0022924. https:\/\/doi.org\/10.1128\/jcm.00229-24.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"1127_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/s1473-3099(21)00452-7","volume":"22","author":"A Penn-Nicholson","year":"2022","unstructured":"Penn-Nicholson A, Georghiou SB, Ciobanu N, et al. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022;22(2):242\u20139. https:\/\/doi.org\/10.1016\/s1473-3099(21)00452-7.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1127_CR14","doi-asserted-by":"publisher","first-page":"14841","DOI":"10.1002\/14651858.CD014841.pub2","volume":"5","author":"S Pillay","year":"2022","unstructured":"Pillay S, Steingart KR, Davies GR, et al. Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database Syst Rev. 2022;5(5):14841. https:\/\/doi.org\/10.1002\/14651858.CD014841.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1127_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02761-22","volume":"11","author":"S Truden","year":"2023","unstructured":"Truden S, Sodja E, \u017dolnir-Dov\u010d M. Drug-resistant tuberculosis on the Balkan peninsula: determination of drug resistance mechanisms with Xpert MTB\/XDR and whole-genome sequencing analysis. Microbiol Spectr. 2023;11(2): e0276122. https:\/\/doi.org\/10.1128\/spectrum.02761-22.","journal-title":"Microbiol Spectr"},{"issue":"6","key":"1127_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01832-22","volume":"61","author":"X Chen","year":"2023","unstructured":"Chen X, Li R, Ge S, et al. Rapid detection of extensive drug resistance by Xpert MTB\/XDR optimizes therapeutic decision-making in rifampin-resistant tuberculosis patients. J Clin Microbiol. 2023;61(6): e0183222. https:\/\/doi.org\/10.1128\/jcm.01832-22.","journal-title":"J Clin Microbiol"},{"key":"1127_CR17","unstructured":"Xpert MTB\/XDR ENGLISH Package Insert 302\u20133514 Rev C. https:\/\/www.cepheid.com\/content\/dam\/www-cepheid-com\/documents\/package-insert-files\/Xpert%20MTB-XDR%20ENGLISH%20Package%20Insert%20302-3514%20Rev%20C.pdf."},{"key":"1127_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1164\/arrd.1963.87.5.775","volume":"87","author":"GP Kubica","year":"1963","unstructured":"Kubica GP, Dye WE, Cohn ML, Middlebrook G. Sputum digestion and decontamination with N-acetyl-l-cysteine-sodium hydroxide for culture of mycobacteria. Am Rev Respir Dis. 1963;87:775\u20139. https:\/\/doi.org\/10.1164\/arrd.1963.87.5.775.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"1127_CR19","first-page":"21","volume":"41","author":"G Canetti","year":"1969","unstructured":"Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Org. 1969;41(1):21.","journal-title":"Bull World Health Org"},{"key":"1127_CR20","unstructured":"Organization WH. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. World Health Organization; 2018."},{"issue":"1","key":"1127_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"issue":"1","key":"1127_CR22","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1038\/s41598-018-21378-x","volume":"8","author":"P Lempens","year":"2018","unstructured":"Lempens P, Meehan CJ, Vandelannoote K, et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep. 2018;8(1):3246. https:\/\/doi.org\/10.1038\/s41598-018-21378-x.","journal-title":"Sci Rep"},{"issue":"11","key":"1127_CR23","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1128\/jcm.43.11.5477-5482.2005","volume":"43","author":"M Zhang","year":"2005","unstructured":"Zhang M, Yue J, Yang YP, et al. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol. 2005;43(11):5477\u201382. https:\/\/doi.org\/10.1128\/jcm.43.11.5477-5482.2005.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"1127_CR24","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/jac\/dku161","volume":"69","author":"T Jagielski","year":"2014","unstructured":"Jagielski T, Baku\u0142a Z, Roeske K, et al. Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2014;69(9):2369\u201375. https:\/\/doi.org\/10.1093\/jac\/dku161.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1127_CR25","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1093\/jac\/dkv253","volume":"70","author":"T Jagielski","year":"2015","unstructured":"Jagielski T, Baku\u0142a Z, Roeske K, et al. Mutation profiling for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2015;70(12):3214\u201321. https:\/\/doi.org\/10.1093\/jac\/dkv253.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1127_CR26","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1128\/aac.01577-08","volume":"53","author":"GE Louw","year":"2009","unstructured":"Louw GE, Warren RM, van Gey Pittius NC, et al. A balancing act: efflux\/influx in mycobacterial drug resistance. Antimicrob Agents Chemother. 2009;53(8):3181\u20139. https:\/\/doi.org\/10.1128\/aac.01577-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1127_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120470","volume":"10","author":"E Avalos","year":"2015","unstructured":"Avalos E, Catanzaro D, Catanzaro A, et al. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS ONE. 2015;10(3): e0120470.","journal-title":"PLoS ONE"},{"issue":"4","key":"1127_CR28","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1128\/aac.01049-15","volume":"60","author":"JY Chien","year":"2016","unstructured":"Chien JY, Chiu WY, Chien ST, et al. Mutations in gyrA and gyrB among fluoroquinolone- and multidrug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2016;60(4):2090\u20136. https:\/\/doi.org\/10.1128\/aac.01049-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1127_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/1574-6968.12401","volume":"353","author":"J Lu","year":"2014","unstructured":"Lu J, Liu M, Wang Y, Pang Y, Zhao Z. Mechanisms of fluoroquinolone monoresistance in Mycobacterium tuberculosis. FEMS Microbiol Lett. 2014;353(1):40\u20138. https:\/\/doi.org\/10.1111\/1574-6968.12401.","journal-title":"FEMS Microbiol Lett"},{"issue":"1","key":"1127_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1574-6976.2005.00002.x","volume":"30","author":"E De Rossi","year":"2006","unstructured":"De Rossi E, A\u00ednsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev. 2006;30(1):36\u201352. https:\/\/doi.org\/10.1111\/j.1574-6976.2005.00002.x.","journal-title":"FEMS Microbiol Rev"},{"key":"1127_CR31","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2147\/idr.S457308","volume":"17","author":"XS Xiong","year":"2024","unstructured":"Xiong XS, Zhang XD, Yan JW, et al. Identification of Mycobacterium tuberculosis resistance to common antibiotics: an overview of current methods and techniques. Infect Drug Resist. 2024;17:1491\u2013506. https:\/\/doi.org\/10.2147\/idr.S457308.","journal-title":"Infect Drug Resist"},{"issue":"8","key":"1127_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.5588\/ijtld.15.0896","volume":"20","author":"S Foongladda","year":"2016","unstructured":"Foongladda S, Banu S, Pholwat S, et al. Comparison of TaqMan(\u00ae) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB. Int J Tuberc Lung Dis. 2016;20(8):1105\u201312. https:\/\/doi.org\/10.5588\/ijtld.15.0896.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"1127_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1128\/aac.01030-10","volume":"55","author":"F Brossier","year":"2011","unstructured":"Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55(1):355\u201360. https:\/\/doi.org\/10.1128\/aac.01030-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1127_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4103\/0971-5916.171272","volume":"142","author":"M Varma-Basil","year":"2015","unstructured":"Varma-Basil M, Prasad R. Dilemmas with ethionamide susceptibility testing of Mycobacterium tuberculosis: a microbiologist & physician\u2019s nightmare. Indian J Med Res. 2015;142(5):512\u20134. https:\/\/doi.org\/10.4103\/0971-5916.171272.","journal-title":"Indian J Med Res"},{"issue":"1","key":"1127_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5588\/ijtld.16.0384","volume":"21","author":"S Banu","year":"2017","unstructured":"Banu S, Rahman MT, Ahmed S, et al. Multidrug-resistant tuberculosis in Bangladesh: results from a sentinel surveillance system. Int J Tuberc Lung Dis. 2017;21(1):12\u20137. https:\/\/doi.org\/10.5588\/ijtld.16.0384.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1127_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.09.027","author":"SMM Rahman","year":"2024","unstructured":"Rahman SMM, Samina P, Rahman T, et al. Isoniazid resistance pattern among pulmonary tuberculosis patients in Bangladesh: an exploratory study. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2024.09.027.","journal-title":"Clin Microbiol Infect"},{"key":"1127_CR37","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: Diagnosis \u2013 Rapid diagnostics for tuberculosis detection World Health Organization; 2024. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/nbk602005\/."},{"key":"1127_CR38","unstructured":"Campaign MA. Access to TB Testing and Treatments: GeneXpert and Delamanid. 2023."},{"key":"1127_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/1471-2334-13-352","volume":"13","author":"M Shah","year":"2013","unstructured":"Shah M, Chihota V, Coetzee G, Churchyard G, Dorman SE. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infect Dis. 2013;13:352. https:\/\/doi.org\/10.1186\/1471-2334-13-352.","journal-title":"BMC Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01127-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01127-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01127-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:20:45Z","timestamp":1744492845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01127-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1127"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01127-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. M. Mazidur Rahman, Noshin Nawer Ruhee, Amiyo Haider, Md Jahid Hasan, Rumana Nasrin, Ahammad Shafiq Sikder Adel, Mohammad Khaja Mafij Uddin, Shahriar Ahmed, Aung Kya Jai Maug, and Sayera Banu declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Institutional Review Board of International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) (Protocol number: PR-21008 and PR-22047), and was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Informed written consents\/assents were obtained from participants prior to enrolling in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}